<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632109</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003878</org_study_id>
    <secondary_id>K23AI113185</secondary_id>
    <nct_id>NCT03632109</nct_id>
  </id_info>
  <brief_title>Gent for Pharyngeal Gonorrhea (GC)</brief_title>
  <official_title>Gentamicin for Pharyngeal Gonorrhea - A Demonstration Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Centers for Disease Control and Prevention has identified antimicrobial-resistant (AMR)&#xD;
      Neisseria gonorrhoeae (NG) as one of the nation's top three urgent AMR threats. Since the&#xD;
      advent of antibiotics in the 1930s, NG has developed resistance to every first-line&#xD;
      antibiotic. Parenteral third-generation cephalosporins are now the only class of drug with&#xD;
      consistent efficacy against NG. New therapies are urgently needed. Although some novel&#xD;
      antimicrobials are under development, reevaluating older drugs is another option for quickly&#xD;
      identifying additional treatments for gonorrhea. We propose a demonstration study to test a&#xD;
      single dose of gentamicin for the treatment of pharyngeal gonorrhea. We chose to focus on&#xD;
      pharyngeal gonorrhea because these infections are common, play an important role in fostering&#xD;
      gonococcal resistance, and are harder to eradicate than genital infections. Although&#xD;
      gentamicin is 91% efficacious for genital NG, its efficacy at the pharynx may be less since&#xD;
      streptomycin, another aminoglycoside previously used to treat gonorrhea, was not effective&#xD;
      for pharyngeal NG. It is unknown if streptomycin's poor efficacy is indicative of limitations&#xD;
      of aminoglycosides as a class. We plan to enroll 60 men who have sex with men in a&#xD;
      demonstration study to be conducted at the Seattle &amp; King County STD Clinic to test the&#xD;
      efficacy of 360 mg of gentamicin given intramuscularly for pharyngeal gonorrhea. Secondary&#xD;
      objectives include determining the ideal pharmacodynamic criterion (comparing in vitro&#xD;
      minimal inhibitory concentrations (MIC) of NG to peak gentamicin serum levels), estimating&#xD;
      resistance induction among treatment failures, and assessing the tolerability of 360 mg of IM&#xD;
      gentamicin.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
      The proposed study aims to evaluate the efficacy of a single intramuscular (IM) dose of&#xD;
      gentamicin in the treatment of pharyngeal gonorrhea. Secondary objectives include documenting&#xD;
      the efficacy stratified by minimal inhibitory concentration (MIC) compared with the&#xD;
      gentamicin peak level in order to estimate a pharmacodynamic criterion. We will also attempt&#xD;
      to determine whether gentamicin monotherapy induces antimicrobial resistance among treatment&#xD;
      failures. Lastly, we will evaluate the tolerability of 360 mg of IM gentamicin, stratified by&#xD;
      subject weight (i.e. weight based dosing). The specific aims are:&#xD;
&#xD;
        1. Determine the proportion of persons whose pharyngeal gonococcal infections are cured&#xD;
           with a single dose of 360mg gentamicin intramuscularly alone.&#xD;
&#xD;
        2. Evaluate the renal safety and tolerability of 360mg IM of gentamicin.&#xD;
&#xD;
        3. Document mean peak gentamicin levels following 360mg IM of gentamicin stratified by&#xD;
           weight.&#xD;
&#xD;
        4. Estimate the best pharmacodynamics criterion (i.e. peak/MIC ratio) for pharyngeal&#xD;
           gonorrhea treated with gentamicin using individual and mean peak gentamicin levels and&#xD;
           NG isolate MIC.&#xD;
&#xD;
        5. Among treatment failures, conduct exploratory analyses comparing pre- and post-treatment&#xD;
           MIC for evidence of induced resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Actual">March 12, 2019</completion_date>
  <primary_completion_date type="Actual">March 12, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure Rate Defined as the Percentage of Persons With Pharyngeal Gonorrhea Treated With Gentamicin 360mg IM Who Have a Negative Culture 4-7 Days Following Treatment</measure>
    <time_frame>4-7 days (+/- 1 day) after treatment</time_frame>
    <description>Negative Pharyngeal Culture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Safety</measure>
    <time_frame>4-7 days (+/- 1 day) after treatment</time_frame>
    <description>Measured by a percent change in serum creatinine from baseline to test of cure (4-7 days following treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of the Injection Gentamicin 360mg IM x 1</measure>
    <time_frame>4-7 days (+/- 1 day) after treatment</time_frame>
    <description>Participant reported pain scale, with 1 being little to no pain, and 10 being the worst pain ever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Gentamicin Levels</measure>
    <time_frame>at 30, 45, or 60 minutes post dose</time_frame>
    <description>serum gentamicin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gentamicin Minimal Inhibitory Concentration (MIC)</measure>
    <time_frame>baseline/enrollment visit</time_frame>
    <description>laboratory defined MIC of infecting strain of N. gonorrhoeae at enrollment visit determined by agar dilution</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Study: Look for Evidence of Induced Resistance</measure>
    <time_frame>4-7 days (+/- 1 day) after treatment</time_frame>
    <description>Among treatment failures, compare pre-treatment and post-treatment minimal inhibitory concentrations (MIC)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Pharyngeal Gonococcal Infection</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gentamicin 360mg IM</intervention_name>
    <description>360mg IM of gentamicin</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persons diagnosed with pharyngeal gonorrhea who are not yet treated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 16 years&#xD;
&#xD;
          -  Receipt of antibiotics in â‰¤30 days&#xD;
&#xD;
          -  Known allergy to any aminoglycoside&#xD;
&#xD;
          -  History of renal disease (including diagnosis of solitary kidney, chronic renal&#xD;
             insufficiency, renal cell carcinoma etc),&#xD;
&#xD;
          -  Use of concurrent nephrotoxic drugs or muscle relaxants&#xD;
&#xD;
          -  History of diabetes&#xD;
&#xD;
          -  History of hearing loss or tinnitus&#xD;
&#xD;
          -  Concurrent infection with syphilis or chlamydia&#xD;
&#xD;
          -  Pregnancy and/or nursing&#xD;
&#xD;
          -  Unable to return for a follow-up visit 4-7 days (+/- 1 day).&#xD;
&#xD;
          -  Study team's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindley A Barbee, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Public Health -- Seattle &amp; King County STD Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <results_first_submitted>July 6, 2020</results_first_submitted>
  <results_first_submitted_qc>July 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2020</results_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Lindley Barbee</investigator_full_name>
    <investigator_title>Assistant Professor, School of Medicine: Department of Medicine: Allergy and Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>gonorrhea</keyword>
  <keyword>pharynx</keyword>
  <keyword>treatment</keyword>
  <keyword>gentamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gonorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03632109/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>Pharyngeal Gonorrhea</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>Pharyngeal Gonorrhea</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" lower_limit="21" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.4" lower_limit="53" upper_limit="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (in)</title>
          <units>in</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.9" lower_limit="68" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" lower_limit="17.9" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.86" lower_limit="0.74" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PrEP Status (Taking HIV PrEP)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of oral sex partners in the last 2 months</title>
          <units>reported sex partners</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cure Rate Defined as the Percentage of Persons With Pharyngeal Gonorrhea Treated With Gentamicin 360mg IM Who Have a Negative Culture 4-7 Days Following Treatment</title>
        <description>Negative Pharyngeal Culture</description>
        <time_frame>4-7 days (+/- 1 day) after treatment</time_frame>
        <population>Positive culture at enrollment and returned for test of cure, or negative culture at enrollment but positive culture at test of cure</population>
        <group_list>
          <group group_id="O1">
            <title>Pharyngeal Gonorrhea</title>
            <description>Evaluable Population</description>
          </group>
        </group_list>
        <measure>
          <title>Cure Rate Defined as the Percentage of Persons With Pharyngeal Gonorrhea Treated With Gentamicin 360mg IM Who Have a Negative Culture 4-7 Days Following Treatment</title>
          <description>Negative Pharyngeal Culture</description>
          <population>Positive culture at enrollment and returned for test of cure, or negative culture at enrollment but positive culture at test of cure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Safety</title>
        <description>Measured by a percent change in serum creatinine from baseline to test of cure (4-7 days following treatment)</description>
        <time_frame>4-7 days (+/- 1 day) after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.&#xD;
gentamicin 360mg IM: 360mg IM of gentamicin</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Safety</title>
          <description>Measured by a percent change in serum creatinine from baseline to test of cure (4-7 days following treatment)</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="0.20" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of the Injection Gentamicin 360mg IM x 1</title>
        <description>Participant reported pain scale, with 1 being little to no pain, and 10 being the worst pain ever.</description>
        <time_frame>4-7 days (+/- 1 day) after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Pharyngeal gonorrhea</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of the Injection Gentamicin 360mg IM x 1</title>
          <description>Participant reported pain scale, with 1 being little to no pain, and 10 being the worst pain ever.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Gentamicin Levels</title>
        <description>serum gentamicin concentration</description>
        <time_frame>at 30, 45, or 60 minutes post dose</time_frame>
        <population>2 participants had missing gentamicin levels</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.&#xD;
gentamicin 360mg IM: 360mg IM of gentamicin</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Gentamicin Levels</title>
          <description>serum gentamicin concentration</description>
          <population>2 participants had missing gentamicin levels</population>
          <units>microgram/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="15" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gentamicin Minimal Inhibitory Concentration (MIC)</title>
        <description>laboratory defined MIC of infecting strain of N. gonorrhoeae at enrollment visit determined by agar dilution</description>
        <time_frame>baseline/enrollment visit</time_frame>
        <population>2 participants were culture negative at enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.&#xD;
gentamicin 360mg IM: 360mg IM of gentamicin</description>
          </group>
        </group_list>
        <measure>
          <title>Gentamicin Minimal Inhibitory Concentration (MIC)</title>
          <description>laboratory defined MIC of infecting strain of N. gonorrhoeae at enrollment visit determined by agar dilution</description>
          <population>2 participants were culture negative at enrollment</population>
          <units>microgram/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Study: Look for Evidence of Induced Resistance</title>
        <description>Among treatment failures, compare pre-treatment and post-treatment minimal inhibitory concentrations (MIC)</description>
        <time_frame>4-7 days (+/- 1 day) after treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at the test of cure visit 4-7 days following dosing.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.&#xD;
gentamicin 360mg IM: 360mg IM of gentamicin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lindley Barbee, Principal Investigator</name_or_title>
      <organization>University of Washington</organization>
      <phone>206.744.2595</phone>
      <email>lbarbee@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

